Stifel analysts confirmed their Buy rating on Denali Therapeutics Inc. (NASDAQ:DNLI) with a steady price target of $37.00. According to InvestingPro data, analysts maintain a Strong Buy consensus with ...
CRISPR technology has radically transformed genetic research, and at the forefront of this transformation is CRISPR screening ...
News Medical on MSN1h
Neuroscientists crack the code of how we make decisions with new mathematical frameworkA new mathematical model sheds light on how the brain processes different cues, such as sights and sounds, during decision ...
The US Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in ...
2-Year U.S. Treasury Note Continuous Contract $102.695-0.027-0.03% 5-Year U.S. Treasury Note Continuous Contract $106.398-0.063-0.06% 10-Year U.S. Treasury Note Continuous Contract $109.156-0.078 ...
CurePSP awarded CARES grants for multi-center projects aimed at improving care, access, and education for patients with PSP, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback